Suven Life up 5% on patents for neuro-degenerative drug
The company was granted patents from Europe and Israel corresponding to the NCEs for the treatment of disorders associated with neuro-degenerative diseases.
By PTI | Updated:
NEW DELHI: Shares of Suven Life Sciences rose over 5 per cent today as the company has been granted one product patent each by Europe and Israel for a drug used in the treatment of neuro-degenerative diseases.
The stock gained 5.22 per cent to Rs 204.30 on BSE.
At NSE, shares of the company went up 5.27 per cent to Rs 204.50.
The company has been granted "one product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a BSE filing today.
The patents are valid through 2030 and 2029 respectively, the company added.
With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel.
The stock gained 5.22 per cent to Rs 204.30 on BSE.
At NSE, shares of the company went up 5.27 per cent to Rs 204.50.
The company has been granted "one product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a BSE filing today.
The patents are valid through 2030 and 2029 respectively, the company added.
With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
